Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 781 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Angiogram Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Comprehensive Imaging of Perforator Vessels and Subcutaneous Vascular Network With No-Exogenous Contrast and Non-Ionizing-Radiation Magnetic Resonance Angiography

NCT03567018
View directory record Official record
Conditions
Perforator Flap Surgery
Interventions
MRI Scan
Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2024
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Oct 23, 2026, 6:08 AM EDT
Completed Not applicable Interventional Results available

Patient Comfort With Vascular Closure

NCT00998023
View directory record Official record
Conditions
Vascular Closure
Interventions
Mynx Vascular Closure Device, AngioSeal Vascular Closure Device
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 23, 2026, 6:08 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

South Asians and Coronary Plaque Registry

NCT05367297
View directory record Official record
Conditions
Coronary Artery Disease, Heart Diseases
Interventions
Coronary CT Angiogram
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 23, 2026, 6:08 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Tebentafusp for Uveal Melanoma

NCT06414590
View directory record Official record
Conditions
Locally Advanced Unresectable Uveal Melanoma
Interventions
Tebentafusp-Tebn
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 23, 2026, 6:08 AM EDT
Completed Not applicable Interventional Results available

NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study

NCT03929913
View directory record Official record
Conditions
Functional Mitral Regurgitation
Interventions
Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 6:08 AM EDT
Completed No phase listed Observational

NA-AION Risk Factors: New Perspectives

NCT05305079
View directory record Official record
Conditions
Non-arteritic Ischemic Optic Neuropathy, Optic Disk Drusen
Interventions
Not listed
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Other
Eligibility
11 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Palo Alto, California • San Francisco, California • Boulder, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 23, 2026, 6:08 AM EDT
Recruiting Phase 1 Interventional

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

NCT06484062
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint, Decitabine and Cedazuridine, Echocardiography Test, Multigated Acquisition Scan
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
23
States / cities
New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 6:08 AM EDT
Recruiting Phase 1Phase 2 Interventional

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

NCT07225985
View directory record Official record
Conditions
Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Bendamustine, Pralatrexate, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Echocardiography Test, Lumbar Puncture, Magnetic Resonance Imaging, Multigated Acquisition Scan, Peripheral Blood Stem Cell Transplantation, Positron Emission Tomography, Questionnaire Administration, Total-Body Irradiation, Biospecimen Collection
Drug · Procedure · Other + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 23, 2026, 6:08 AM EDT
Completed Not applicable Interventional

A-priori Versus Provisional Heparin on Radial Artery Occlusion After Transradial Coronary Angiography and Patent Hemostasis

NCT01489917
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Patent hemostasis and heparin
Other
Lead sponsor
Olivier F. Bertrand
Other
Eligibility
18 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Oct 23, 2026, 6:08 AM EDT
Completed Not applicable Interventional Results available

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

NCT00660543
View directory record Official record
Conditions
Adult Brain Glioblastoma
Interventions
Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 23, 2026, 6:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

NCT02555189
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v7
Interventions
Enzalutamide, Ribociclib, Laboratory Biomarker Analysis, Pharmacological Study, Biospecimen Collection, Biopsy, Echocardiography, Multigated Acquisition Scan, Bone Scan, Computed Tomography, Magnetic Resonance Imaging
Drug · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
4
States / cities
Ann Arbor, Michigan • Buffalo, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 23, 2026, 6:08 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

NCT03939897
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Abemaciclib, Biopsy Procedure, Biospecimen Collection, Copanlisib Hydrochloride, Diagnostic Imaging Testing, Echocardiography Test, Fulvestrant, Multigated Acquisition Scan
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Costa Mesa, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 6:08 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

NCT05432791
View directory record Official record
Conditions
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib, Pazopanib, Temozolomide, Trabectedin, Transthoracic Echocardiography Test
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
144
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 6:08 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

NCT00853827
View directory record Official record
Conditions
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Interventions
Placebo, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
54
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 23, 2026, 6:08 AM EDT
Withdrawn Not applicable Interventional

Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF

NCT04684212
View directory record Official record
Conditions
Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
Interventions
LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
Device · Drug
Lead sponsor
Brian O'Neill MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 23, 2026, 6:08 AM EDT
Recruiting Early Phase 1 Interventional

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

NCT06735690
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Multigated Acquisition Scan, Positron Emission Tomography, Transplant Conditioning, X-Ray Imaging
Procedure · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 23, 2026, 6:08 AM EDT
Completed No phase listed Observational

The PERFusion Use in Stroke Evaluation Study

NCT01387113
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Computed tomography perfusion imaging
Other
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 23, 2026, 6:08 AM EDT
Recruiting Phase 1 Interventional

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

NCT04375631
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
Interventions
Cladribine, Cyclophosphamide, Cyclosporine, Cytarabine, Filgrastim, Hematopoietic Cell Transplantation, Mitoxantrone, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Idarubicin, Fludarabine, Multigated Acquisition Scan, Echocardiography Test, X-Ray Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 6:08 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

NCT05936229
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions
Interferon Beta-1A, X-Ray Imaging, Echocardiography, Multigated Acquisition Scan, Computed Tomography, Positron Emission Tomography, Lumbar Puncture, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection, Biopsy
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 23, 2026, 6:08 AM EDT
Withdrawn Phase 4 Interventional

Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan

NCT01508780
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT), Boston Scientific Intravascular Ultrasound
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 23, 2026, 6:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Use of Diagnostic Dye to Identify Areas of Leakeage,in the Retina, Prior to Receiving Focal Laser Treatment

NCT01792141
View directory record Official record
Conditions
Macular Edema
Interventions
Not listed
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 15, 2013 · Synced Oct 23, 2026, 6:08 AM EDT
Completed No phase listed Observational

The Distal (SnUffbox) Radial artERy Access for Coronary Angiography and Interventions (SUPER-Prospective)

NCT03794687
View directory record Official record
Conditions
Coronary Angiography
Interventions
Left heart catheterization
Procedure
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 23, 2026, 6:08 AM EDT
Terminated No phase listed Observational

Use of Magnetocardiography in Evaluation of Patients Going for Cardiac Catheterization

NCT04044391
View directory record Official record
Conditions
Acute Coronary Syndrome, Coronary Artery Stenosis, Myocardial Ischemia
Interventions
CardioFlux Magnetocardiograph
Diagnostic Test
Lead sponsor
Genetesis Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Detroit, Michigan • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 23, 2026, 6:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Magnetic Resonance Imaging for Evaluating Kidney Function

NCT00006173
View directory record Official record
Conditions
Healthy, Renovascular Hypertension
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 6:08 AM EDT